Mammalian cells that exhibit the Multidrug Resistance or MDR phenotype produce high levels of a membrane protein (the P-glycoprotein) that acts as a broad spectrum pump that removes from the cell a number of cancer chemotherapeutic agents (reviewed by Bradley et al., 1988 and Moscow et al., 1988) . This phenotype has been implicated in intrinsic and acquired drug resistance in a number of human tumours (Fojo et al., 1987a (Fojo et al., , 1987b Kahehi et al., 1988; Linsenmeyer et al., 1992) . While a number of agents have been shown to reverse the MDR phenotype, their use in the clinical situation with resistant tumours has been restricted due to doselimiting toxicities (Dalton et al., 1989 : Durie et al., 1988 .
Recently, we found that a relatively pharmacologically inert substance, Cremophor EL, will reverse the MDR phenotype in cells in culture at concentrations likely to be readily achievable clinically (Woodcock et al., 1990) . Our conclusions have since been confirmed by other studies (Schuurhuis et al., 1990; Friche et al., 1990) . Cremophor EL is a polyethylene oxide modified castor oil used as a solubilising agent for drugs and vitamins for both oral and parenteral administration. We have examined a chemically diverse selection of surface active agents to define the structural requirements for MDR reversal by Cremophor El through determining its effects on uptake and efflux of a fluorescent drug eliminated by cells containing an active P-glycoprotein pump. We have also examined the effect of Cremophor EL on the fluidity of cell membranes. Finally, we report the effect of coadministration of Cremophor EL on the survival time of mice bearing an MDR tumour treated with a chemotherapeutic drug affected by the MDR phenotype.
Materials and methods

Materials
Cremophor EL and Solutol HSI 5 were obtained from BASF Fine Chemicals (Melbourne, Australia and Ludwigshafen, Germany, respectively) . Detergents #1 to #12 (Table I) were a set supplied by Boehringer Mannheim GmbH, Germany (Cat no. 1124714 Octylphenolpoly(ethyleneglycolether)IO 7.
Octylphenolpoly(ethyleneglycolether)7 (Triton X-1 14)
8.
Dodecylpoly(ethyleneglycolether)9 (Thesit) 9.
Isotridecylpoly(ethyleneglycolether)n 10. divalent ions) with vigorous mixing. This dispersion was mixed with the cell suspension and a given concentration of Cremophor in PBS, the final cell density being 0.5 x 106ml-'h. Probe uptake was for 1 h at room temperature in the dark. Fluorescence polarisation measurements, corrected for the scatter of the excitation beam, were made with a T-format fluorimeter as previously described (Thulborn & Sawyer, 1978) . The results are expressed as fluorescence anisotropy, r = (V-H)/(V+2H), where V and H are the intensities of the vertical and horizontal components of the emitted light respectively. No attempt was made to convert the anisotropy values into microviscosities because of the assumptions necessary in that conversion (Sawyer, 1988) .
Results
Comparison of detergents
The activity of the P-glycoprotein pump in cells in culture was assayed by measuring the intracellular level of the fluorescent drug DNR that is excluded by cells actively expressing the MDR phenotype. Reversal of the MDR phenotype causes increased intracellular DNR concentrations that can be readily measured by flow cytometry (Frankfurt, 1987 Figure 1 (Panels a, b and c respectively). (Solutol is primarily polyethoxylated 1 2-hydroxystearate.) These three surfactants were chosen for more detailed study because they were the least toxic of the surfactants that were active in reversing drug exclusion. The cell types employed were the drug-sensitive human leukaemic cell line CEM and its MDR derivative, R100 cells, that can grow in 100 ng ml-' of VLB and that show a 40 to 50 fold overexpression of the mdrl mRNA (Woodcock et al., 1990) . While all three agents produced similar maximal intracellular DNR levels, this was achieved at 1:104 with Tween-80 and Solutol but required 1:103 of Cremophor. These experiments involve reversal of the MDR phenotype in a human cell line that has amplified and overexpresses the human mdrl gene. This effect of Cremophor on MDR is not cell line or species specific since a similar concentration dependency of MDR reversal was observed with a multidrug resistant mouse cell line, P388/ ADR ( Figure Id) . Quantitation of mdrl mRNA by slot blot analysis indicated a 15 fold higher level of transcription in the P388/ADR cells compared to the P388 parental cells (not illustrated).
Cells recover rapidly from the effect of Cremophor on reversal of DNR exclusion. The drug resistant cells were incubated for 1 h with the optimal dilution of Cremophor (1:1000), washed, and incubated for an additional 1 h in medium containing DNR but no Cremophor. The subsequent intracellular DNR levels were not significantly different from those in control cells that had not been exposed to Cremophor (Figure la) . Hence by 1 h after removal of the Cremophor, the MDR cells had recovered the ability to exclude drug.
The reduction in DNR levels in cells incubated in higher concentrations of Tween 80 (Figure 1 b) was not due primarily to inhibition of uptake but rather to gross cellular damage. When the integrity of cells in the presence of Cremophor and Tween 80 was examined (Figure 2A) Figure 2B, bottom row) . However, CEM cells were found to be more sensitive than the MDR derivative to the lytic effects of Solutol ( Figure 2B , top row).
Uptake and efflux studies The effect of Cremophor on the rate of DNR uptake in drug sensitive and resistant human cells was monitored by continuous assessment of mean intracellular DNR fluorescence over 120 s (Figure 3a) or 600 s (Figure 3b ) following addition of DNR to the cells. The initial rate of DNR uptake in the absence of Cremophor was equivalent in both cell lines except that, after 2 to 3 min, the intracellular DNR levels in the MDR cells began to plateau (Figure 3a and 3b ). In the presence of Cremophor, initial uptake rate was reduced in both cell types, but total uptake continued to increase in the MDR cell line (Figure 3a ). This could be seen more clearly when intracellular DNR levels were monitored over a longer time interval (Figure 3b) the absence of Cremophor pretreatment. However, in the presence of Cremophor, intracellular DNR levels continued to increase linearly beyond 10m. Hence, despite the reduction in initial uptake rate when Cremophor is present, significantly increased intracellular levels of DNR will ultimately be obtained in the MDR cells (Figure la) . The effect of Cremophor on DNR exclusion appears to be established rapidly. When the MDR cells (without pretreatment with Cremophor) were incubated with DNR plus Cremophor, the uptake rate of DNR was equivalent to that in MDR cells pretreated for 1 h with Cremophor (Figure 3b) .
Reversal of DNR exclusion by Cremophor in cells expressing the MDR phenotype appears to be mediated primarily by effects on drug efflux. The MDR cell line R100 cells and the parental CEM cells were preincubated in complete growth medium with DNR in the presence of Cremophor. Cells were then rapidly washed free of DNR and the time course of DNR efflux monitored by flow cytometry in the absence or presence of Cremophor. While Cremophor had no appreciable effect on drug efflux from the non-MDR cell type, DNR efflux in the presence of Cremophor in the MDR cell line was reduced significantly to be almost equivalent to that in the drug sensitive parental line (Figure 4 ).
Effect of Cremophor EL on membranefluidity Fluorescence anisotropy of the membrane probe DPH was used to ascertain whether Cremophor had an effect on the fluidity of the cell membranes that might explain any disruption of function of integral membrane proteins such as Pglycoprotein. The fluorescence anisotropy of R100 cells (in the absence of Cremophor) was 1.11 ± 0.07 times that of CEM cells (n = 4 separate experiments). For both cell types, anisotropy was reduced significantly by Cremophor ( Figure  5 ). For the MDR cell line, anisotropy was reduced progressively with increasing concentrations of Cremophor, reaching a plateau value that was <20% of the initial value at 2: 104 of Cremophor (equivalent to a theoretical Cremophor concentration of 0.375 mM) ( Figure 5 ). However, for the sensitive cell line, anisotropy did not decrease until >1: 10, decreasing progressively thereafter. To examine the reversibility of the Cremophor effect on membrane fluidity, Cremophor at 2: 103 was added to CEM and R100 cells in normal growth medium. One hour later, cells were washed with PBS-EDTA and anisotropy determined. Cremophor on membrane fluidity with the washed CEM and R100 cells giving anisotropy values of 100 ± 1% and 101 ± 1.5% of the control cell membranes respectively.
In vitro and in vivo studies with a mouse MDR transplantable tumour
In in vitro cytotoxicity assays with P388 cell line and its ADR-resistant derivative P388/ADR, Cremophor reduced the IC50 by >4 fold for the P388/ADR cells in a dose dependent manner (Figure 6 ). The concentrations of Cremophor emloyed, 0.5, 1, and 2 parts in 105 in the medium, were equivalent to 1/40, '/20, and '/lo of the IC50 for Cremophor as a single agent in these cells. Cremophor potentiation of drug effectiveness was also observed in vivo ( Figure  7 ). There was a statistically significant difference in the duration of survival between the four groups (P = 0.0002, logrank test) with median survival of 10.5 days for the untreated mice, 15.5 days for the mice treated with adriamycin alone, 12 days for mice treated with Cremophor alone, and 22.5 days for mice treated with both adriamycin and Cremophor. Cremophor was found to have a major effect on the microviscosity of cell membranes. The sharp and substantial decrease in fluorescence anisotropy shows that Cremophor causes a significant fluidisation of the membranes of both CEM and R100 cells. DPH is known to distribute between the plasma membrane and subcellular membranes of cells. Thus, its fluorescence anisotropy reflects the microviscosities of all cell membranes weighted according to the partition 1 distribution of DPH. There were similar concentration dependencies of drug exclusion and alterations in fluorescence anisotropy in R100 cells. In addition, the effect of Cremophor on membrane fluidity and DNR exclusion were both readily reversible in R100 cells. These data would be consistent with some causal relationship between a major surfactant-induced disruption of the internal structures of cell membranes and an inhibition of activity of membranespanning proteins such as the P-glycoprotein. The observation that Cremophor inhibits [3H]-Azidopine photoaffinitylabelling of the P-glycoprotein (Friche et al., 1990) could be due to a direct competition for binding to the drug pump between the Azidopine and Cremophor. Alternatively, it might equally well be interpreted as the P-glycoprotein being incapable of binding and/or transporting hydrophobic compounds such as Azidopine when the cell membrane structure, of which it is an integral part, is so perturbed by the Cremophor.
Since cells that overexpress the mouse and human Pglycoproteins show similar responses to Cremophor, the use of a murine transplantable tumour cell line should constitute a valid model for the reversal of drug resistance in human cells. In vitro, non-toxic concentrations of Cremophor substantially reduced the ICs for adriamycin in an MDR cell line, P388/ADR. In vivo, coadministration of Cremophor with adriamycin significantly increased the survival time of mice transplanted with an adriamycin-resistant tumour compared with those treated with adriamycin alone. We do not have sufficient data to suggest that such a treatment regimen is at all optimal for overcoming this form of drug resistance.
The T/C for survival of 195% for the tumour-bearing mice treated with a combination of adriamycin plus Cremophor was greater than that reported for an adriamycin-resistant P388 tumour treated with adriamycin plus calcium channel blockers where the best combination gave a T/C of 143% (Tsuruo et al., 1983) . However, direct comparison of these results is difficult since, in our experiments, the adriamycinresistant tumour was more responsive to adriamycin alone (147% T/C) than in these earlier experiments (109% to 117% T/C). In this and in other experiments, Cremophor alone produced some marginal increase in survival in mice. The polyethoxylated surfactant Tween 80 has also been reported to exhibit some intrinsic antitumour activity (Crispins & Sorenson, 1988) .
These data imply that a reformulation of a number of currently used cancer chemotherapeutic agents to include sufficient quantities of Cremophor or some other polyethoxylated solubilising agent might achieve a significant increase in efficacy against human tumours that express high levels of the P-glycoprotein. Such tumours would include those that have developed higher expression levels during tumour progression and, not inconceivably, tumours derived from tissues that normally express high levels of the P-glycoprotein that are characteristically refractory to cancer chemotherapeutic agents, at least as currently formulated (Fojo et al., 1987a (Fojo et al., , 1987b Kahehi et al., 1988) .
